Navigation Links
Stents That Release Medication To Check Artery Narrowing

Compared to bare metal stents, placement of stents that release the medication paclitaxel reduces the risk// of the artery re-narrowing nine months following angioplasty for patients with complex coronary artery lesions, according to an article in the September 14 issue of JAMA.

Drug-eluting stents have revolutionized the treatment of atherosclerotic coronary artery disease, according to background information in the article. These stents (which release medications, such as sirolimus and paclitaxel) have been shown to safely reduce clinical and angiographic restenosis (narrowing again of the artery after treatment) compared with bare metal stents. Enrollment in the trials for these stents, however, was restricted to relatively simple stenoses (vessel diameter of 2.5-3.75 mm with lesion length 30 mm or less). More than 55 percent of lesions currently treated with these bioactive devices may fall outside this range.

Researchers of Columbia University Medical Center and Cardiovascular Research Foundation, New York had conducted a study (the TAXUS V trial) to investigate the safety and efficacy of a paclitaxel-eluting stent in a patient population with more complex coronary lesions than previously studied. The trial, conducted from February 2003 to March 2004 at 66 academic and community-based institutions, included 1,156 patients who underwent stent implantation in a single coronary artery stenosis (vessel diameter, 2.25-4.0 mm; lesion length, 10-46 mm), including 664 patients (57.4 percent) with complex or previously unstudied lesions (requiring 2.25-mm, 4.0-mm, and/or multiple stents) and had 9-month clinical and angiographic follow-up.

Angiographic restenosis was reduced among patients receiving 2.25-mm stents (49.4 percent vs. 31.2 percent), 4.0-mm stents (14.4 percent vs. 3.5 percent), and multiple stents (57.8 percent vs. 27.2 percent).

The TAXUS V trial investigated the use of paclitaxel-eluting stents in a patient populati
'"/>




Page: 1 2

Related medicine news :

1. Stronger Backing for Drug-Coated Stents
2. Drug-Coated Stents – Proven to be More Effectiv
3. The Efficacy Of Newer Stents Questioned
4. Analyzing The Side Effects Of Sirolimus Stents
5. Drug-Coated Stents Work Better In Diabetic Patients After Angioplasty
6. Drug-Eluting Stents Ensure Patency Of The Saphenous Vein Grafts
7. Effectiveness Of Drug-Releasing Coronary Stents
8. Nitiol Stents A Better Alternative for the Conventional Stents
9. Does Life Saving Stents Actually Carry The Risk Of Blood Clots?
10. Bottleneck for Neck Stents - May Enhance Risk of Stroke, Says a Study
11. Using Heart Stents Tends to Form More Clots
Post Your Comments:
(Date:7/18/2008)...e-USNewswire/ -- Two consumer,groups today filed a...ent,on human embryonic stem cells held by the Wisc...r Watchdog, formerly The Foundation for Taxpayer a...on appealed to the U.S. Patent,Office,s Board of A...d,WARF,s patent after the two groups requested a r...
(Date:7/18/2008)...ectrum of the animal and human world will be exami...ongress, hosted by the International Society for B...l University in Ithaca., In addition to talks and...y sessions on: , Suzanne Alonzo, assistant prof...rsity, on "When Theory Meets Data: What We Don,t K...
(Date:7/18/2008)...ss campaign to raise awareness, of the importanc...cine compliance rates across the Uni.../ -- The COSHAR Foundation, a,nonprofit organizati...empowerment with a focus on minority and disadvant...areness Day on Saturday, July 19 in conjunction,wi...
(Date:7/18/2008)...dicine for psychiatric patients , , FRID...e found more evidence that a person,s genetic make... to the antidepressant Celexa (citalopram). , S...ound that variations in the serotonin transporter ...his drug, one of the family of medications known a...
Breaking Medicine News(10 mins):Health News:Consumer Groups File Appeal on Challenge of Human Stem Cell Patent Held By WARF 2Health News:The COSHAR Foundation Participates in Annual Women's Health Awareness Day 2Health News:The COSHAR Foundation Participates in Annual Women's Health Awareness Day 3Health News:Gene Variations May Predict Antidepressant Response 2
...gy of enhancing communication with family members ...reatly reduce post-traumatic stress disorder, anx...cording to a study to be presented at the American...ference in San Francisco on Monday, May 21. The m...
...eley and Davis campuses of the University of Calif...ected with HIV successfully inactivates the free-...chnique - heating a glass jar of expressed breast ...or single burner - will provide hope that mothers...
...espond favorably to the drug temozolomide when use...treatment appears to work best in people missing a...ntific journal of the American Academy of Neurolog...ith low grade gliomas, a slow-growing type of brai...
...n diagnosed with breast cancer should either start...ey should continue exercising, for it will help th...archers analysed 500 women, who had survived breas...ctivity, and more specifically the intensity and a...
Other Medicine News:Health News:Improved Communication may Help to Accept the Death of Loved Ones With Poise 2Health News:Flash-heating Inactivates HIV in Breast Milk: Study 2Health News:Flash-heating Inactivates HIV in Breast Milk: Study 3Health News:Exercise may Help Breast Cancer Patients to Lead a Healthy Life 2
(Date:7/16/2008)...orts Pivotal Phase 2b Clinical Trials of First, ...f Cystic Fibrosis -, SOUTH PLAINFIELD, N.J. and B...tics, Inc. (PTC) and Cystic Fibrosis Foundation Th...f the Cystic Fibrosis Foundation, today,announced ...ort development,of PTC124, the PTC,s new investiga...
(Date:7/16/2008)...ly 16 /- MAP,Pharmaceutical...ve results,from a Phase 2 study evaluating the saf...in adult asthmatics were published in the July,iss...armaceuticals is,developing MAP0004, an orally inh... treatment for migraine., The study results, whic...
(Date:7/15/2008)...ewswire/ -- Abeome Corporation, a,Georgia-based bi...investment by Cato BioVentures and a collaboration...arch and development organization. The investment,...lopment of Abeome,s lead,ovarian cancer project., ...he development of,monoclonal antibodies and Abeome...
(Date:7/15/2008)...of Phase III Trials of Light Infusion Therapy,in H...Cancer and Phase I/II and Phase IIa Beni..., July 15 /- Light Sciences Oncology,...ight Infusion Therapy(TM),(Litx(TM)) to treat canc...as raised $40.1 million in a Series C round of fin...
Breaking Medicine Technology:PTC Therapeutics Announces $25 Million Award From Cystic Fibrosis Foundation Therapeutics for Development of PTC124 2PTC Therapeutics Announces $25 Million Award From Cystic Fibrosis Foundation Therapeutics for Development of PTC124 3PTC Therapeutics Announces $25 Million Award From Cystic Fibrosis Foundation Therapeutics for Development of PTC124 4MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research and Opinion 2MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research and Opinion 3MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research and Opinion 4Abeome and Cato Research to Collaborate on Ovarian Cancer Therapeutic 2Light Sciences Oncology Raises $40.1 Million in Series C Financing 2WuXi PharmaTech Completes Acquisition of AppTec 2919 1WuXi PharmaTech Completes Acquisition of AppTec 2919 2Survey 3A Massachusetts Employers Employees Paying Most for Health Care Plans 10689 1Survey 3A Massachusetts Employers Employees Paying Most for Health Care Plans 10689 2Survey 3A Massachusetts Employers Employees Paying Most for Health Care Plans 10689 3DURECT Corporation Invites You to Join Its Fourth Quarter 2007 Earnings Conference Call 2917 1MITs McGovern Institute researchers awarded 248 5M to study brain basis of autism and dyslexia 10682 1MITs McGovern Institute researchers awarded 248 5M to study brain basis of autism and dyslexia 10682 2
...ENCE, Italy - 8 March 2007 - Cancer drug,developer...unces,positive initial findings from its second, c...cell lung cancer. , This 30-patient trial tested a...rboplatin and paclitaxel chemotherapy.,Investigato...of,patients showed disease stabilisation, while on...
...evelopment program of first-in-class CB1,antagonis...ion and,avoid image as life-style drug , BARCELONA...ce,firm La Merie S.L. reported today that Sanofi-A...ia (rimonabant) has at least,five competitors in c...rlier phases of R&D. While Acomplia received E...
Other Medicine Technology:Antisoma plc (UK) - Second lung cancer trial adds to positive data,on AS1404 2Antisoma plc (UK) - Second lung cancer trial adds to positive data,on AS1404 3Weight Management is Not Enough for Cannabinoid Type 1 (CB1),Receptor Antagonists to Become a Commercial Success 2Weight Management is Not Enough for Cannabinoid Type 1 (CB1),Receptor Antagonists to Become a Commercial Success 3
Take Performance to a Higher Level.
The MULTI-LINK PIXEL Coronary Stent System was designed to address the challenges of small vessel treatment in patients with abrupt or threatened abrupt closure (ATC).
FemoStop plus system is a femoral compression system for hemostasis management. It provides a comfortable and efficient "hands off method of compressing the femoral artery and vein after diagnostic
...eal the arterial puncture site. Duett is the only ...e tissue tract with a flowable procoagulant. Usin...ulant - the Duett sealing device is designed to ra...nique in its ability to quickly seal the entire pu...
Medicine Products: